I want to tell you a little bit about what we're doing uh at Regeltech. [clears throat and cough] We're looking to solve a problem with chronic low back pain caused by degenerative disc The solution that we have for it is hydrophil. It's a permanent interdiscal implant that we put in with a needle. We've done 75 patients today. Earliest patients are out over three years. The satisfaction survey in these patients is over 90%. Which is really, really big. 90% approval from these patients. They like like what this is. Here's the overview of patient improvement so far. On the left, we have what's called ODI, which is your your chart of how the patients are doing in their normal daily activities. And you can see how much the decrease has been. It usually happens pretty quick in the first month. And the right is the pain. Uh from a one to 10 pain, patients are starting off with a seven and a half all the way down to where you see at two and a half, three years, 1.7, which is a dramatic drop in in pain in these patients. These patients are in chronic pain on a daily what's what's out there now for them? So they start off using conservative care, which is on the left, physical therapy, exercise, pain medications, and then probably advanced to epidural pain On the right you see surgical the surgical um things that they can go to. Fusion, spinal cord stimulator or total disc replacement. The surgical things are all pretty big, pretty invasive. Um spinal cord implant is a total uh it's implanted in you. It's electrical device. Why not hydroill in the middle? Let's try hydroll first. See if it works. It'll never stop you from going to the other surgical things if you need to, but there's a good chance you'll never need to get there with a simple It's a big market in the US. The pop we're looking at population of 25 years and older. Our average patient to date is about 52 years old in the 75 patients we've done. The youngest patient has been 21. The oldest patient is 20 is 85. So chronic low back pain about 13% of that population is 30 million people to degenerative disc disease. The ones that's due to degenerative disease is 10 million. And then what we need is a competent annulus. So is it annulus ring a fibrous annulus ring around in made up of the disc that needs to be competent. It can't have large tears or our gel is just going to go right out to large tears and we found that out. So we have to heat up the gel before it goes in. It goes in kind of like a glue substance and then it sets up when it comes down to temperature. But if it goes in and there's a large tear, it's going to come out. So we do something ahead of time called a discoraphy where they inject a die into the disc and we can see how well that an analyst is confident or not but it's still a very large percentage of the patients we say 60%. But total addressal market of $21 billion at a $3,500 ASP. Um we kind of broke it down a little bit as to where you know because that number is so big. Um but you look at these patients on the bottom have already reached out have already had injections or some type of procedure so far. So even at that lower number it's 2.2 billion which is a very large market. That's just US. The EU market is very similar actually a little bit bigger if you count all the EU countries together but it's a big market um big market to address right now. Technology overview. Hydrophill is made of common polymers of PVA, PVP, and PEG and a very specific manufacturing order. We put a little bit of sterile barium in there so you can see it under X-ray and under radio. Okay. We heat the gel up in the morning before we do procedures. Usually we stack cases. So we'll heat up the gel ahead of time. It sits there and once the needle's in place, it's ready to go in. So you can prep these devices all early in the morning. We're doing what's called a nucleus augmentation. So, we're not taking any of the native nucleus material out of the disc. We're just adding this to what's in the disc already. It's a quick procedure. Um, I've been in 90% of our cases, it usually takes once the needle's in place, which can take different people different time, but usually three to five minutes. This takes another three to five minutes to put the gel in. You can see over here, this is degenerative disc disease. And I'll give you a little bit. This is called the modified furman scale. Grade one and grade two. You can see the white in the disc. That's hydration. These discs are in good shape. They're very well hydrated. They're in good shape. But you can see as we go down the scale and over here, grade five, grade six, grade seven, grade eight. It gets darker and darker and it gets thinner and thinner. So that disc is collapsing the whole time. We really think we work well in what we've seen in the four through eight. So those moderate to severe patients is where hydro hydro really works well. We have broad IP s secured um to 2039 where Europe, US, Europe and Japan right now. Um but we have really good IP um that's all already done. This is a case that we did in Colombia in uh 2020. One of our first patients uh 55year-old female. Just want to show you on the left. This is a divided screen. And so on the left you see the needle that's already in place in the disc. On the right attaching the device to the patient to the needle hub and we're going to turn down on the device which is pushing the plunger down which is going to start to move the gel out of the needle. And you'll start to see the gel come out here at the end of the needle. This is a threeminute video but I sped it up so it's quick for presentation purposes. But you see the gel coming out. He's looking down on the the end of the device. There's a pressure gauge. We want to make sure we don't get overpressurized as we're putting the gel in. And he's also looking at the fluo screen that you're looking at right now to see how well it's filling the disc space. You can see he just continues to look at it and then fill the space. It's almost full at this point. He's going to take the device off in a second on the right. And then we put a stylate down there and let it sit for about 15 minutes in place. So the gel has a chance to set up in the disc and doesn't come out when we pull the needle out with it at the same time. Here's some pictures now in this in the X-ray after the fact. The gel looks, you saw it in the last picture, it looked black on Flora, it looks white here. So this is a patient at 30 days bending forward and bending backwards. Flexion and extension. So we're going to show you they continue their flexion and extension. Don't lose any range of motion. As you can see, there are improvements along the way at 30 days, 6 months, and 365 days at one year. The gel is in place. The patient's able to move forward and backwards. It looks just the same almost from start to finish. And huge improvement in uh ODI and in NRS and pain scores. We started a pivotal trial in the US. We also have a very good advisory team of US surgeons, interventional radiologists, interventional pain doctors, and a Canadian pain doctor who has a lot of experience doing 35 of our patients to date. Our pivotal trial is 225 patients with a control group being conservative care. So, our patients don't know if they got gel or not during the procedure, they don't know. But the ones that got conservative care, ours are getting hydroll. It's a one-year followup time and it's powered for success at 90% power. We have CMDR. We got that back in April and we're looking for partners to commercialize in Europe, the UAE, and Japan right now as we continue going towards FDA approval in the States. FDA approval is probably going to be two and a half, three years out. So the highlights to date, we have breakthrough device status in the US and we're enrolling on our trial. This is a perccutaneous treatment with excellent outcomes to date. We receive CMDR. We also have our ISO certification. I have a really good team we've put together, experienced team that's been with me over a couple different companies. And we have broad IP portfolio in the US, Europe, and Japan. I put this slide up, but I just found out this morning that we've raised, but we have a commitment on five million of the 10 million we have left. So, we already have five million of that. So, right now, I'm just looking for another five million to fill out the A- round that we have going right now. So, let's change the standard of care and for these patients and give them something that's quick, it's efficient, it works for them. That's where we are. Thank you very much. [applause]